← Back to Press Releases May 08, 2024 at 8:00 am ETX101: A potential one-time, disease-modifying gene regulation therapy targeting the underlying cause of SCN1A+ Dravet syndrome Share Post Email Copy Link Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more Cell-Selective Targeting and Regulation The precision gene therapies being developed at Encoded are potentially capable of targeting specific cell types or levels of expression to address a range of disease mechanisms. Learn more
